Efavirenz: History, Development and Future [PDF]
Biomolecules, 2022 Efavirenz (Sustiva®) is a first-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat human immunodeficiency virus (HIV) type 1 infection or to prevent the spread of HIV.
Bárbara Costa, Nuno Vale
doaj +3 more sources
CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with early Alzheimer’s disease [PDF]
Alzheimer’s Research & Therapy, 2022 Background Efavirenz is an anti-HIV drug, and cytochrome P450 46A1 (CYP46A1) is a CNS-specific enzyme that metabolizes cholesterol to 24-hydroxycholesterol (24HC).
Alan J. Lerner +12 more
doaj +3 more sources
Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. [PDF]
PLoS ONE, 2013 We evaluated the importance of ethnicity and pharmacogenetic variations in determining efavirenz pharmacokinetics, auto-induction and immunological outcomes in two African populations.ART naïve HIV patients from Ethiopia (n = 285) and Tanzania (n = 209 ...
Eliford Ngaimisi +13 more
doaj +5 more sources
Effect of Efavirenz on UDP-Glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 Activities in Human Liver Microsomes [PDF]
Molecules, 2012 Efavirenz is a non-nucleoside reverse transcriptase inhibitor used for the treatment of human immunodeficiency virus type 1 infections. Drug interactions of efavirenz have been reported due to in vitro inhibition of CYP2C9, CYP2C19, CYP3A4, and UDP ...
Hye Suk Lee +4 more
doaj +2 more sources
Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis [PDF]
, 2011 Article approval pendingEvidence of the risk of birth defects with efavirenz use is limited. We updated a meta-analysis of birth defects in infants with first trimester efavirenz exposure up to July 2011.
Alexandra Calmy +14 more
core +4 more sources
Pharmacokinetics, pharmacogenetics, and toxicity of co-administered efavirenz and isoniazid [PDF]
Southern African Journal of HIV MedicineBackground: CYP2B6 slow metabolisers have higher efavirenz concentrations, which are further increased by isoniazid inhibiting efavirenz’s accessory metabolic pathway.
Jessica Taylor +6 more
doaj +2 more sources
A Population Pharmacokinetic Approach to Understand the Effect of Efavirenz on CYP3A Activity in Healthy Volunteers Using Midazolam as a Probe [PDF]
CPT: Pharmacometrics & Systems PharmacologyEfavirenz induces and inhibits multiple drug‐metabolizing enzymes, contributing to significant drug–drug interactions. This study quantified the impact of multiple doses of efavirenz on CYP3A activity via midazolam metabolism using a population ...
Kimberly S. Collins +6 more
doaj +2 more sources
Liver Enzyme Abnormalities and Associated Risk Factors in HIV Patients on Efavirenz-Based HAART with or without Tuberculosis Co-Infection in Tanzania. [PDF]
, 2012 To investigate the timing, incidence, clinical presentation, pharmacokinetics and pharmacogenetic predictors for antiretroviral and anti-tuberculosis drug induced liver injury (DILI) in HIV patients with or without TB co-infection.
A Habtewold +62 more
core +30 more sources
Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells. [PDF]
PLoS ONE, 2015 Cancer prevention and therapy in HIV-1-infected patients will play an important role in future. The non-nucleoside reverse transcriptase inhibitors (NNRTI) Efavirenz and Nevirapine are cytotoxic against cancer cells in vitro.
Markus Hecht +8 more
doaj +3 more sources
Contraception: X, 2020 Objectives: Our primary objective was to compare geometric mean levonorgestrel concentrations between levonorgestrel implant users who were or were not taking the antiretroviral efavirenz, for up to 30 months after implant initiation.
Jennifer H. Tang +11 more
doaj +1 more source